Back to search results

Understanding Sickle Cell Trait (AUNT) Study

This observational study aims to better understand Sickle Cell Trait (SCT), a genetic condition where you carry one copy of the sickle cell gene. Researchers will collect blood and urine samples to look at the different amounts of hemoglobin (a protein in red blood cells) in people with SCT. The goal is to learn more about how SCT affects the body and if it leads to any health problems. You can join if you are 18 or older, suspect you have SCT, and are willing to be tested to confirm it. The study is currently unclear on its recruitment status.

Study design
This is an observational study that plans to enroll 1000 participants.
What's involved
You will have blood and urine collected at the beginning of the study.
Compensation
Not stated in the trial record.
Follow-up
Your hemoglobin variant levels will be measured throughout the study, which is expected to last an average of 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06071377

Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT)

Recruiting
Not specifiedAges 18+Observational
National Alliance for Sickle Cell Centers
~1,000 participants
Updated 2025-11-06 on ClinicalTrials.gov
What's tested:Biologic Specimen Collection

At a glance

Recruiting sites
10 of 10 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Hemoglobin variant quantification
Measured over Through study completion, an average of 2 years

Conditions

Sickle Cell Trait

Explore related trials

Sickle Cell TraitHemoglobin S

NCT06071377

Where you'd take part

This study runs at 10 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Duke University

    Durham, North Carolinastudy coordinator listed

    Recruiting

  • East Carolina University

    Greenville, North Carolinastudy coordinator listed

    Recruiting

  • Functional Fluidics

    Detroit, Michiganstudy coordinator listed

    Recruiting

  • Indiana University

    Indianapolis, Indianastudy coordinator listed

    Recruiting

  • Loma Linda University Health Care

    Loma Linda, Californiastudy coordinator listed

    Recruiting

  • Nationwide Children's Hospital

    Columbus, Ohiostudy coordinator listed

    Recruiting

  • Nemours Children's Hospital

    Wilmington, Delawarestudy coordinator listed

    Recruiting

  • University of Alabama

    Birmingham, Alabamastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Julie Kanter, MD · PRINCIPAL_INVESTIGATOR · National Alliance for Sickle Cell Centers

Who to contact

Julie Kanter, MD
[email protected]
(202) 596-1548
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Hemoglobin variant quantificationThrough study completion, an average of 2 years

    Determine range of variability in baseline %HbS in SCT subjects and relationship of baseline %HbS to markers of hemolysis (LDH, reticulocytes, haptoglobin), coagulopathy (D-dimer), and renal disease (urine albumin/creatinine ratio)